Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fragility Fracture

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Fragility Fracture. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-004766-17 Sponsor Protocol Number: zoledronate-fract-65-85yr Start Date*: 2021-06-30
    Sponsor Name:Region Uppsala
    Full Title: The Fragility Fracture Trial (FFT): A randomized, double-blind, placebo-controlled trial to investigate whether zoledronic acid prevents new fractures in older adults with a recent non-hip, non-ver...
    Medical condition: Non-hip, non-vertebral fragility fracture
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000123-41 Sponsor Protocol Number: B3D-EW-GHDW Start Date*: 2012-09-20
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures
    Medical condition: Postmenopausal women with established osteoporosis and at least two moderate or one severe prevalent fragility fracture.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10031288 Osteoporosis with fracture LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) HU (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001778-40 Sponsor Protocol Number: VITAMINA_D Start Date*: 2017-10-11
    Sponsor Name:Leonor Cuadra Llopart
    Full Title: A Prospective Randomized Trial Comparing the Effect of 2 vitamin D supplementation regimens in elderly people after hip fracture surgery
    Medical condition: Hip fracture and vitamin D deficiency
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022587-12 Sponsor Protocol Number: VitK Start Date*: 2015-01-20
    Sponsor Name:Guy's and St. Thomas' NHS Foundation Trust
    Full Title: The Additive effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis
    Medical condition: Post-menopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    20.1 10028395 - Musculoskeletal and connective tissue disorders 10031286 Osteoporosis senile LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031283 Osteoporosis fracture LLT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10017082 Fracture due to osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020081-22 Sponsor Protocol Number: R&D 2185 Start Date*: 2011-02-08
    Sponsor Name:North Bristol NHS Trust
    Full Title: The administration of Parathyroid hormone affects functional recovery from pertrochanteric fractured neck of femur: A prospective randomised comparative pilot study with blinded objective functiona...
    Medical condition: Osteoporotic or low energy pertrochanteric hip fractures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-006017-38 Sponsor Protocol Number: RGB-14-101 Start Date*: 2021-07-13
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A Randomised, Double-blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) CZ (Completed) HU (Completed) BG (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015058-38 Sponsor Protocol Number: OR09/9018 Start Date*: 2010-10-22
    Sponsor Name:University of Leeds
    Full Title: Improving the outcome for patients after osteoporotic femoral fractures
    Medical condition: OSTEOPOROTIC FEMORAL FRACTURE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005343-23 Sponsor Protocol Number: ADAIDO Start Date*: 2021-05-28
    Sponsor Name:IRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A
    Full Title: Effect of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non me...
    Medical condition: post-menopausal osteoporosis in women with non-metastatic hormonal receptor positive (HR+) breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10049088 Osteopenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000434-35 Sponsor Protocol Number: 20120156 Start Date*: 2013-12-10
    Sponsor Name:Amgen, Inc
    Full Title: A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With...
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-012926-35 Sponsor Protocol Number: 5442-001-02 Start Date*: 2009-09-28
    Sponsor Name:Merck & Co, Inc.
    Full Title: A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK-5442 in the Treatment of Postmenopausal Women with Osteoporosis
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10031282 Osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003512-40 Sponsor Protocol Number: 20150120 Start Date*: 2018-03-05
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Heal...
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001153-17 Sponsor Protocol Number: 262 Start Date*: 2008-06-16
    Sponsor Name:MSD
    Full Title: Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combinat...
    Medical condition: Postmenopausal women with osteoporosis at increased risk of falls.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) LT (Completed) GB (Completed) BE (Completed) LV (Completed) FR (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006597-23 Sponsor Protocol Number: UX143-CL301 Start Date*: Information not available in EudraCT
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-Blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta.
    Medical condition: Osteogenesis imperfecta (OI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) DK (Prematurely Ended) DE (Ongoing) IT (Ongoing) PL (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003888-56 Sponsor Protocol Number: 20192022 Start Date*: 2021-01-30
    Sponsor Name:Department of Nephrology, Herlev & Gentofte Hospital, Herlev Hospital
    Full Title: Treatment of adynamic bone disorder with parathyroid hormone in patients with chronic kidney disease
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10060881 Adynamic bone disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004972-74 Sponsor Protocol Number: 20160227 Start Date*: 2020-09-15
    Sponsor Name:Amgen Inc.
    Full Title: An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
    Medical condition: Osteogenesis imperfecta (OI) is a group of genetic skeletal disorders characterized by increased bone fragility, low bone mass , and increased bone turnover contributing to osteoporosis, fracture...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GR (Completed) IT (Ongoing) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003129-23 Sponsor Protocol Number: 04/MR/111 Start Date*: 2006-04-18
    Sponsor Name:Belfast Health and Social Care Trust, Musgrave Park Hospital
    Full Title: Prevention and Treatment of Steroid-Induced Osteopenia in children and adolescents with rheumatic diseases
    Medical condition: Children and adolescents with Juvenile Idiopathic arthritis (JIA), Juvenile dermatomyositis (JDMS) Juvenile systemic lupus erythematosis (JSLE) Vasculitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007456-34 Sponsor Protocol Number: 3100N0-2213-WW Start Date*: 2009-09-04
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: Estudio de fase 2, multicéntrico, aleatorizado, controlado con producto activo, de grupos paralelos, búsqueda de dosis y de la seguridad de la proteína morfogenética de hueso humano recombinante 2 ...
    Medical condition: Sujetos con disminución de la densidad mineral ósea (DMO) en riesgo de fractura de cadera
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    9.1 10031282 Osteoporosis PT
    Population Age: Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) PL (Completed) FI (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003033-41 Sponsor Protocol Number: 2005040 Start Date*: 2006-03-20
    Sponsor Name:Procter & Gamble Technical Centres Limited
    Full Title: A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomi...
    Medical condition: Osteoporosis is a systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and susceptibility to fracture. ...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10031285 PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003228-22 Sponsor Protocol Number: AC16092 Start Date*: 2016-12-14
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid
    Medical condition: Osteogenesis imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) DK (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA